COMPOSITIONS AND METHODS FOR TREATING BIPOLAR DISORDER

• US 20110038807A1
• Filed: 08/14/2009
• Published: 02/17/2011
• Est. Priority Date: 08/14/2009
• Status: Abandoned Application

• Current Assignee: Demitri Papolos
• Original Assignee: Demitri Papolos
• Inventors: Papolos, Demitri
• Application Number:
  US12/541,403
• Publication Number:
  US 20110038807A1
• Time in Patent Office: Days
• US Class Current: 424/45
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/24 Antidepressants

Abstract

The present invention is directed to a method for treating bipolar disorder, childhood-onset bipolar disorder, and associated symptoms. The method includes administering to a subject in need of such treatment a dose of ketamine sufficient to alleviate symptoms associated with bipolar disorder and childhood-onset bipolar disorder.

Claims

1. A method for treating childhood-onset bipolar disorder in a subject comprising intranasally administering a therapeutic composition comprising ketamine to a subject in need thereof.

2. The method of claim 1, wherein the subject is at least 18 months of age.

3. The method of claim 1, wherein the subject is a child between the stages of 18 months and puberty.

4. The method of claim 1, wherein the ketamine composition is self-administered nasally on an outpatient basis.

5. The method of claim 1, wherein said method comprises intranasally administering a single dose of ketamine.

6. The method of claim 1, wherein said method comprises intranasally administering multiple doses of ketamine.

7. The method of claim 1, wherein said method comprises intranasally administering a dose of ketamine of approximately 0.01 to approximately 1 mg/kg of body weight.

8. The method of claim 1, wherein the dose of ketamine is approximately 0.05 to approximately 0.7 mg/kg of body weight.

9. The method of claim 1, wherein the ketamine composition further comprises a dispersant.

10. The method of claim 1, wherein the ketamine composition is a dry powder aerosol formulation in which the ketamine is present as a finely divided powder.

11. The method of claim 1, wherein the ketamine composition is a liquid aerosol formulation.

12. A method for treating mania in a subject comprising intranasally administering a therapeutic composition comprising ketamine to a subject in need thereof.

13. The method of claim 12, wherein the subject is at least 18 months of age.

14. The method of claim 12, wherein the subject is a child between the stages of 18 months and puberty.

15. The method of claim 12, wherein the ketamine composition is self-administered nasally on an outpatient basis.

16. The method of claim 12, wherein said method comprises intranasally administering a single dose of ketamine.

17. The method of claim 12, wherein said method comprises intranasally administering multiple doses of ketamine.

18. The method of claim 12, wherein said method comprises intranasally administering a dose of ketamine of approximately 0.01 to approximately 1 mg/kg of body weight.

19. The method of claim 12, wherein the dose of ketamine is approximately 0.05 to approximately 0.7 mg/kg of body weight.

20. The method of claim 12, wherein the ketamine composition is a dry powder aerosol formulation in which the ketamine is present as a finely divided powder.

21. The method of claim 12, wherein the ketamine composition is a liquid aerosol formulation.

22. The method of claim 12, wherein the subject is an adult having childhood-onset bipolar disorder.